PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000850820.70181.23 |
| _version_ | 1827336987141472256 |
|---|---|
| author | H. Elsabah N. Kassem A. Gulied R. Taha H. Elomri H. Cherif |
| author_facet | H. Elsabah N. Kassem A. Gulied R. Taha H. Elomri H. Cherif |
| author_sort | H. Elsabah |
| collection | DOAJ |
| first_indexed | 2024-03-07T18:43:23Z |
| format | Article |
| id | doaj.art-4e541fcf01ae463480b79d877c81619d |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T18:43:23Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-4e541fcf01ae463480b79d877c81619d2024-03-02T03:29:00ZengWileyHemaSphere2572-92412022-06-0161868186910.1097/01.HS9.0000850820.70181.23202206003-01868PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCEH. Elsabah0N. Kassem1A. Gulied2R. Taha3H. Elomri4H. Cherif51 Hematology2 Pharmacy department, Hamad medical corporation, Doha, Qatar2 Pharmacy department, Hamad medical corporation, Doha, Qatar1 Hematology1 Hematology1 Hematologyhttp://journals.lww.com/10.1097/01.HS9.0000850820.70181.23 |
| spellingShingle | H. Elsabah N. Kassem A. Gulied R. Taha H. Elomri H. Cherif PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE HemaSphere |
| title | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_full | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_fullStr | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_full_unstemmed | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_short | PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE |
| title_sort | pb1997 daratumumab lenalidomide bortezomib and dexamethasone for transplant eligible newly diagnosed multiple myeloma outcome and safety profile from a real world single center experience |
| url | http://journals.lww.com/10.1097/01.HS9.0000850820.70181.23 |
| work_keys_str_mv | AT helsabah pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT nkassem pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT agulied pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT rtaha pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT helomri pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience AT hcherif pb1997daratumumablenalidomidebortezomibanddexamethasonefortransplanteligiblenewlydiagnosedmultiplemyelomaoutcomeandsafetyprofilefromarealworldsinglecenterexperience |